Serum Biomarkers and Neoadjuvant Chemotherapy in Breast Cancer
Author Information
Author(s): Nolen Brian M, Marks Jeffrey R, Ta'san Shlomo, Rand Alex, Luong The Minh, Wang Yun, Blackwell Kimberly, Lokshin Anna E
Primary Institution: University of Pittsburgh Cancer Institute
Hypothesis
Can serum biomarker profiles predict the response to neoadjuvant chemotherapy in locally advanced breast cancer?
Conclusion
Serum biomarker profiles may help predict treatment response and outcomes in patients undergoing neoadjuvant chemotherapy for breast cancer.
Supporting Evidence
- Biomarker levels were compared with clinical and pathologic treatment responses.
- Multivariate analysis revealed biomarker panels that could differentiate treatment response groups.
- Elevated serum levels of IL-6, IL-8, and MMP-9 correlated with improved clinical response.
Takeaway
Doctors can look at certain blood markers to see how well chemotherapy is working for women with advanced breast cancer.
Methodology
Serum samples were collected from 44 patients and analyzed for 55 biomarkers using Luminex assays.
Limitations
The study had a relatively small sample size, which may limit the predictive power of the findings.
Participant Demographics
Patients with locally advanced breast cancer (stage IIB or III), total enrolled 47, 44 completed treatment.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website